中文摘要：

背景与目的肺癌严重威胁人类生存健康,有效的肿瘤标志物可以辅助诊断、判断预后和指导治疗。本研究旨在检测非小细胞肺癌患者肿瘤组织和血浆中烯醇化酶1（alpha-enolase,ENO1）蛋白水平,初步探讨ENO1作为肺癌相关蛋白标志物的可能性。方法采用Western blot方法检测16例肺鳞癌患者的肿瘤组织及其配对正常肺组织中ENO1蛋白水平。采用双抗体夹心酶联免疫吸附分析（enzyme-linked immunosorbent assay,ELISA）测定42例健康体检者、34例肺部良性疾病患者和84例非小细胞肺癌患者三组人群血浆中ENO1蛋白水平。结果在87.5%（14/16）的肺鳞癌患者肿瘤组织中ENO1蛋白表达量高于其配对正常肺组织;非小细胞肺癌患者血浆中ENO1蛋白水平高于健康体检者（P=0.031）和肺部良性疾病者（P=0.019）,且ENO1蛋白在肺腺癌患者血浆中的水平高于肺鳞癌患者（P=0.023）。结论非小细胞肺癌肿瘤组织和血浆中ENO1蛋白水平升高,提示ENO1可作为潜在的非小细胞肺癌相关血浆蛋白标志物。

英文摘要：

Background and objective Proper tumor markers are useful to diagnosis,prognosis and treatment for lung cancer. The aim of this study is to examine the levels of alpha-enolase（ENO1） protein in the tumor tissues and peripheral plasma samples obtained from non-small cell lung cancer（NSCLC） patients,and evaluate its potential clinical significance. Methods The ENO1 protein levels in the tumor tissues and corresponding normal tissues from 16 cases of lung squamous cell carcinoma were analyzed by Western blot. The ENO1 protein levels in the plasma samples from 42 healthy individuals,34 patients with lung benign disease and 84 patients with NSCLC were measured by double antibody sandwich enzyme-linked immunosorbent assay. Results For 87.5%（14/16） of the patients with lung squamous cell carcinoma,the ENO1 protein level in the tumor tissues was higher than that in the corresponding normal lung tissues. The ENO1 protein level in the plasma of NSCLC patients was significantly higher than that in the plasma of healthy individuals（P=0.031） and patients with lung benign disease（P=0.019） . Furthermore,the ENO1 protein level was significantly higher in the plasma of patients with lung adenocarcinoma than that of patients with lung squamous cell carcinoma. Conclusion The elevated levels of ENO1 protein in the tumor tissues and the plasma samples from NSCLC patients indicate ENO1 may be a candidate biomarker of lung cancer.